Geode Capital Management LLC Increases Position in GH Research PLC (NASDAQ:GHRS)

Geode Capital Management LLC increased its holdings in GH Research PLC (NASDAQ:GHRS) by 4.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 72,513 shares of the company’s stock after purchasing an additional 3,092 shares during the quarter. Geode Capital Management LLC owned 0.14% of GH Research worth $508,000 at the end of the most recent reporting period.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GHRS. Guggenheim began coverage on GH Research in a research report on Thursday, March 13th. They set a “buy” rating and a $32.00 target price on the stock. Royal Bank of Canada assumed coverage on shares of GH Research in a research report on Friday, March 7th. They set an “outperform” rating and a $31.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Stifel Nicolaus increased their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, Cantor Fitzgerald started coverage on GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research presently has a consensus rating of “Buy” and an average price target of $30.86.

GH Research Stock Performance

NASDAQ GHRS opened at $11.39 on Friday. The stock’s fifty day moving average is $10.26 and its two-hundred day moving average is $9.75. The firm has a market capitalization of $592.60 million, a P/E ratio of -14.42 and a beta of 0.84. GH Research PLC has a fifty-two week low of $6.00 and a fifty-two week high of $20.50.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. As a group, sell-side analysts forecast that GH Research PLC will post -0.8 EPS for the current year.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).